The frontier of cancer immunotherapy is shifting in a way that challenges a long-held assumption: that mRNA technology is primarily a delivery mechanism for antigens. A new synthesis of the field argues that next-generation mRNA vaccines, particularly those paired with engineered extracellular vesicles, are capable of fundamentally reprogramming the immunological character of tumors themselves — not merely directing immune cells toward them.
This comprehensive review, published in Precision Clinical Medicine, maps the convergence of several advancing disciplines. On the biochemical side, chemical nucleotide modifications, optimized untranslated regions, and refined codon architecture are extending transcript stability while reducing off-target inflammatory signaling — a key barrier to clinical tolerability. Neoantigen identification has moved beyond single-omic approaches, with multiomic workflows integrating genomics, transcriptomics, immunoproteomics, and HLA-binding prediction algorithms enabling truly patient-specific target prioritization. Critically, the review highlights how engineered lipid nanoparticles and exosome-based delivery platforms are being surface-functionalized to preferentially traffic toward antigen-presenting cells and lymphoid tissues, dramatically improving immunological engagement. Perhaps most significant is the detailed mechanistic account of how vaccine-induced cytokine signaling intersects with epigenetic reprogramming — a process the authors argue can reverse local immune tolerance and convert immunologically "cold" tumors, which historically evade immune destruction, into "hot" tumors susceptible to effector T-cell infiltration.
While the science described is compelling, important caveats apply. This is a review article, not a clinical trial; the most transformative claims about epigenetic TME remodeling remain largely preclinical or early-phase. The history of cancer immunotherapy is littered with mechanisms that were persuasive in vitro but proved difficult to sustain in the complex human tumor environment. Still, the convergence of mRNA biochemistry, exosome engineering, and epigenetic modulation represents a genuinely integrative advance over first-generation vaccine platforms. If even partial TME reprogramming can be achieved reliably in humans, the therapeutic ceiling for personalized cancer vaccines rises considerably.